pioglitazone has been researched along with Head and Neck Neoplasms in 4 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
Head and Neck Neoplasms: Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Head and neck cancer is a major source of morbidity and mortality worldwide." | 2.50 | PPARγ in head and neck cancer prevention. ( Burotto, M; Szabo, E, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 2 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rosas, RR | 1 |
| Nachbor, KM | 1 |
| Handley, N | 2 |
| Mathison, G | 1 |
| Wuertz, BR | 1 |
| Ba'th, F | 1 |
| Ondrey, FG | 1 |
| Yang, TH | 1 |
| Xirasagar, S | 1 |
| Cheng, YF | 1 |
| Wu, CS | 1 |
| Kao, YW | 1 |
| Shia, BC | 1 |
| Lin, HC | 1 |
| Burotto, M | 1 |
| Szabo, E | 1 |
| Eide, J | 1 |
| Taylor, R | 1 |
| Wuertz, B | 1 |
| Gaffney, P | 1 |
| Ondrey, F | 1 |
1 review available for pioglitazone and Head and Neck Neoplasms
| Article | Year |
|---|---|
PPARγ in head and neck cancer prevention.
Topics: Clinical Trials as Topic; Disease Progression; Evidence-Based Medicine; Head and Neck Neoplasms; Hum | 2014 |
3 other studies available for pioglitazone and Head and Neck Neoplasms
| Article | Year |
|---|---|
Preclinical evidence for pioglitazone and bexarotene combination in oral cancer chemoprevention.
Topics: Bexarotene; Chemoprevention; Head and Neck Neoplasms; Humans; Mouth Neoplasms; Pioglitazone; United | 2022 |
Association between pioglitazone use and head and neck cancer: Population-based case-control study.
Topics: Case-Control Studies; Head and Neck Neoplasms; Humans; Hypoglycemic Agents; Pioglitazone; Taiwan | 2020 |
PPARγ targeted oral cancer treatment and additional utility of genomics analytic techniques.
Topics: Animals; Carcinoma, Squamous Cell; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Genomic | 2017 |